Clinical Trials
16 trialsNCT06239480 2026-03-27
SELVA
Palvella Therapeutics, Inc.
Phase 3 Active not recruiting
NCT05696444 2025-11-25
Medtronic Hugoâ„¢ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
Medtronic - MITG
Phase NA Active not recruiting
NCT06499142 2024-07-12
Parakeet
Neurovision Medical Products Inc
Phase NA Active not recruiting
NCT01653392 2024-03-15
BioThrax® (Anthrax) Vaccine in Pregnancy Registry
Emergent BioSolutions
Completed
NCT05013944 2024-01-30
AnovaOS Network Powered Patient Registry
Anova Enterprises, Inc
Recruiting
NCT01077856 2022-09-13
VIP
Merck Sharp & Dohme LLC
Completed
NCT03678467 2022-05-27
EB-CMF
Epibone, Inc.
Phase 1/2 Unknown
NCT03317366 2021-08-06
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
No longer available
NCT04848376 2021-04-19
Post-Market Clinical Follow-up Study of A-SPINE's Products
A-Spine Asia Co., Ltd.
Unknown
NCT00093600 2020-12-19
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Novartis
Phase 1 Completed
NCT01343693 2020-01-06
MaxAn
Zimmer Biomet
Completed
NCT01175785 2019-03-05
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
Nohla Therapeutics, Inc.
Phase 2 Completed
NCT01031368 2019-03-01
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
Nohla Therapeutics, Inc.
Phase 1 Completed
NCT00081055 2014-12-04
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
Mesoblast, Ltd.
Phase 2 Withdrawn
NCT00891137 2014-10-27
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cellerant Therapeutics
Phase 1 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed